Publikationen, an denen er mitarbeitet Vicente Estrada Pérez (33)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2023

  1. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

2022

  1. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. Blood Bacterial Profiles Associated With Human Immunodeficiency Virus Infection and Immune Recovery

    The Journal of infectious diseases, Vol. 223, Núm. 3, pp. 471-481

  2. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  3. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

  4. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  3. Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects

    Frontiers in Immunology, Vol. 11

2019

  1. Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)

    Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

2018

  1. Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota

    AIDS, Vol. 32, Núm. 10, pp. 1229-1237

  2. Interplay between gut microbiota metabolism and inflammation in HIV infection

    ISME Journal, Vol. 12, Núm. 8, pp. 1964-1976

2017

  1. Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2016 para el tratamiento antirretroviral inicial en adultos infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 2, pp. 88-99

  2. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

    Mucosal Immunology, Vol. 10, Núm. 5, pp. 1279-1293